11/24/2015 - 1:31pm

Eli Lilly and Co.’s Petrazza in a trial extended the lives of patients who took the drug in combination with two forms of chemotherapy to 11.5 months. 

11/20/2015 - 3:55pm

Specialty medications represent only 1% of all prescriptions but, in 2014, these medications resulted in over 31% of all drug spending.

11/20/2015 - 9:29am

The average annual cost of a specialty medication used on a chronic basis exceeded $53,000 in 2013, which is more than the median U.S. household income, AARP noted. 

11/19/2015 - 1:37pm

The healthcare logistics industry has seen significant improvements in product security and regulatory compliance across the supply chain. 

11/18/2015 - 11:49am

AxelaCare enhances OptumRx’s ability to deliver care to the growing number of consumers managing complex conditions through at-home infusions.

11/17/2015 - 9:16am

Tagrisso is an EGFR-tyrosine kinase inhibitor, a targeted cancer therapy, designed to inhibit both the activating, sensitizing mutations, and T790M, the genetic mutation responsible for EGFR-TKI treatment resistance in up to approximately two-thirds of cases of EGFRm advanced NSCLC. 

11/13/2015 - 3:18pm
The drug was granted Fast Track, Breakthrough, Priority Review and Accelerated Approval status by the FDA and has shown an objective response rate of 59% with a median duration of about 12.4 months. 
11/12/2015 - 12:22pm

The moves are part of a strategic move to align efforts for internal improvement, the specialty pharmacy operator said. 

11/11/2015 - 2:35pm

A new drug has been approved that, in conjunction with vemurafenib, is meant to treat metastatic melanoma that can't be removed through surgery with a certain gene mutation.